Zanidatamab
Zanidatamab is a bispecific monoclonal antibody targeting two non-overlapping epitopes on the HER2 receptor (human epidermal growth factor receptor 2), providing dual HER2 blockade that inhibits HER2 dimerization, activates antibody-dependent cellular cytotoxicity (ADCC), and increases receptor internalization and degradation more effectively than single-epitope anti-HER2 agents. It is under investigation for HER2-amplified or HER2-overexpressing cancers including gastroesophageal adenocarcinoma and biliary tract cancer. Its bispecific architecture may overcome resistance mechanisms to single-epitope HER2-targeted therapies.
治療領域
作用機序
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
Zanidatamab is a bispecific monoclonal antibody targeting two non-overlapping epitopes on the HER2 receptor (human epidermal growth factor receptor 2), providing dual HER2 blockade that inhibits HER2 dimerization, activates antibody-dependent cellular cytotoxicity (ADCC), and increases receptor internalization and degradation more effectively than single-epitope anti-HER2 agents. It is under investigation for HER2-amplified or HER2-overexpressing cancers including gastroesophageal adenocarcinoma and biliary tract cancer. Its bispecific architecture may overcome resistance mechanisms to single-epitope HER2-targeted therapies.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Zanidatamab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4650256. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="zanidatamab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/zanidatamab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/zanidatamab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/zanidatamab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="zanidatamab"></drugfyi-drug>